PMID- 36502755
OWN - NLM
STAT- MEDLINE
DCOM- 20230119
LR  - 20230119
IS  - 1950-6007 (Electronic)
IS  - 0753-3322 (Linking)
VI  - 158
DP  - 2023 Feb
TI  - Attenuated WNV-poly(A) exerts a broad-spectrum oncolytic effect by selective 
      virus replication and CD8+ T cell-dependent immune response.
PG  - 114094
LID - S0753-3322(22)01483-4 [pii]
LID - 10.1016/j.biopha.2022.114094 [doi]
AB  - As an emerging tumor therapy, ideal oncolytic viruses preferentially replicate in 
      malignant cells, reverse the immunosuppressive tumor microenvironment, and 
      eventually can be eliminated by the patient. It is of great significance for 
      cancer treatment to discover new excellent oncolytic viruses. Here, we found that 
      WNV live attenuated vaccine WNV-poly(A) could be developed as a novel ideal 
      oncolytic agent against several types of cancers. Mechanistically, due to its 
      high sensitivity to type Iota interferon (IFN-Iota), WNV-poly(A) could specifically 
      kill tumor cells rather than normal cells. At the same time, WNV-poly(A) could 
      activate Dendritic cells (DCs) and trigger tumor antigen specific response 
      mediated by CD8 + T cell, which contributed to inhibit the propagation of 
      original and distal tumor cells. Like intratumoral injection, intravenous 
      injection with WNV-poly(A) also markedly delays Huh7 hepatic carcinoma (HCC) 
      transplanted tumor progression. Most importantly, in addition to an array of 
      mouse xenograft tumor models, WNV-poly(A) also has a significant inhibitory 
      effect on many different types of patient-derived tumor tissues and HCC 
      patient-derived xenograft (PDX) tumor models. Our studies reveal that WNV-poly(A) 
      is a potent and excellent oncolytic agent against many types of tumors and may 
      have a role in metastatic and recurrent tumors.
CI  - Copyright (c) 2022 The Authors. Published by Elsevier Masson SAS.. All rights 
      reserved.
FAU - Liu, Jing
AU  - Liu J
AD  - Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, 
      Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China; 
      University of Chinese Academy of Sciences, Beijing, China.
FAU - Hu, Yan-Yan
AU  - Hu YY
AD  - Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, 
      Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China; 
      University of Chinese Academy of Sciences, Beijing, China.
FAU - Zhang, Qiu-Yan
AU  - Zhang QY
AD  - Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, 
      Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China.
FAU - Zhang, Ya-Nan
AU  - Zhang YN
AD  - Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, 
      Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China.
FAU - Li, Na
AU  - Li N
AD  - Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, 
      Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China; 
      University of Chinese Academy of Sciences, Beijing, China.
FAU - Zhang, Zhe-Rui
AU  - Zhang ZR
AD  - Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, 
      Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China; 
      University of Chinese Academy of Sciences, Beijing, China.
FAU - Zhan, Shun-Li
AU  - Zhan SL
AD  - Beijing Shunlei Biotechnology Co. Ltd., Beijing, China.
FAU - Gao, Lei
AU  - Gao L
AD  - Beijing Shunlei Biotechnology Co. Ltd., Beijing, China.
FAU - Deng, Cheng-Lin
AU  - Deng CL
AD  - Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, 
      Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China.
FAU - Li, Xiao-Dan
AU  - Li XD
AD  - Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, 
      Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China.
FAU - Yuan, Shao-Peng
AU  - Yuan SP
AD  - Beijing Shunlei Biotechnology Co. Ltd., Beijing, China.
FAU - He, Yuan-Qiao
AU  - He YQ
AD  - Center of Laboratory Animal Science, Nanchang University, Nanchang, China.
FAU - Ye, Han-Qing
AU  - Ye HQ
AD  - Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, 
      Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China; 
      University of Chinese Academy of Sciences, Beijing, China. Electronic address: 
      yehq@wh.iov.cn.
FAU - Zhang, Bo
AU  - Zhang B
AD  - Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, 
      Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China; 
      University of Chinese Academy of Sciences, Beijing, China. Electronic address: 
      zhangbo@wh.iov.cn.
LA  - eng
PT  - Journal Article
DEP - 20221208
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
SB  - IM
MH  - Animals
MH  - Mice
MH  - *Carcinoma, Hepatocellular
MH  - CD8-Positive T-Lymphocytes
MH  - Cell Line, Tumor
MH  - Immunity
MH  - *Liver Neoplasms/therapy
MH  - Neoplasm Recurrence, Local
MH  - *Oncolytic Viruses/metabolism
MH  - Tumor Microenvironment
MH  - Virus Replication
OTO - NOTNLM
OT  - Broad spectrum
OT  - CD8+ T cell
OT  - IFN-I-dependent selectivity
OT  - Immunity therapy
OT  - Oncolytic virus
OT  - WNV-poly(A)
COIS- Conflict of interest statement The authors declare no potential conflicts of 
      interest.
EDAT- 2022/12/13 06:00
MHDA- 2023/01/19 06:00
CRDT- 2022/12/12 08:50
PHST- 2022/10/06 00:00 [received]
PHST- 2022/11/23 00:00 [revised]
PHST- 2022/12/05 00:00 [accepted]
PHST- 2022/12/13 06:00 [pubmed]
PHST- 2023/01/19 06:00 [medline]
PHST- 2022/12/12 08:50 [entrez]
AID - S0753-3322(22)01483-4 [pii]
AID - 10.1016/j.biopha.2022.114094 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2023 Feb;158:114094. doi: 10.1016/j.biopha.2022.114094. Epub 
      2022 Dec 8.